CN113577363A - Composite wound dressing and preparation method thereof - Google Patents
Composite wound dressing and preparation method thereof Download PDFInfo
- Publication number
- CN113577363A CN113577363A CN202110938732.5A CN202110938732A CN113577363A CN 113577363 A CN113577363 A CN 113577363A CN 202110938732 A CN202110938732 A CN 202110938732A CN 113577363 A CN113577363 A CN 113577363A
- Authority
- CN
- China
- Prior art keywords
- graphene oxide
- silver
- chitosan
- nano
- wound dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002131 composite material Substances 0.000 title claims abstract description 80
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 101
- 229910021389 graphene Inorganic materials 0.000 claims abstract description 96
- 229920001661 Chitosan Polymers 0.000 claims abstract description 71
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 71
- 239000000243 solution Substances 0.000 claims abstract description 32
- 239000011259 mixed solution Substances 0.000 claims abstract description 23
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000006185 dispersion Substances 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 239000004094 surface-active agent Substances 0.000 claims abstract description 10
- 229910001961 silver nitrate Inorganic materials 0.000 claims abstract description 9
- 238000001132 ultrasonic dispersion Methods 0.000 claims abstract description 5
- 239000000047 product Substances 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 14
- 239000002244 precipitate Substances 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- 235000010443 alginic acid Nutrition 0.000 claims description 10
- 229920000615 alginic acid Polymers 0.000 claims description 10
- 238000009210 therapy by ultrasound Methods 0.000 claims description 10
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 9
- 239000004594 Masterbatch (MB) Substances 0.000 claims description 9
- 229940072056 alginate Drugs 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- -1 polypropylene Polymers 0.000 claims description 8
- 239000004317 sodium nitrate Substances 0.000 claims description 7
- 235000010344 sodium nitrate Nutrition 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000012265 solid product Substances 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 108010022355 Fibroins Proteins 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012286 potassium permanganate Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 229940015043 glyoxal Drugs 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 description 25
- 239000003242 anti bacterial agent Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 229910052709 silver Inorganic materials 0.000 description 11
- 239000004332 silver Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 8
- 241000222122 Candida albicans Species 0.000 description 7
- 229940095731 candida albicans Drugs 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000010355 oscillation Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 238000005485 electric heating Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical group [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000010436 fluorite Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012213 gelatinous substance Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 229920006280 packaging film Polymers 0.000 description 1
- 239000012785 packaging film Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Abstract
The application provides a preparation method of a composite wound dressing, which comprises the following steps: dispersing graphene oxide and a surfactant in water to obtain a graphene oxide dispersion liquid, wherein the mass ratio of the graphene oxide to the surfactant is (125-: 1; adding a silver nitrate solution into the graphene oxide dispersion liquid to obtain a mixed solution, wherein the volume ratio of the graphene oxide dispersion liquid to the silver nitrate solution is 1: 1; performing microwave treatment on the mixed solution to obtain a nano silver/graphene oxide composite material; adding chitosan into a solvent, then adding the nano-silver/graphene oxide composite material, and performing ultrasonic dispersion to obtain a reaction solution, wherein the mass ratio of the chitosan to the nano-silver/graphene oxide composite material is (5-20): 6; adding a cross-linking agent to obtain the chitosan/nano silver/graphene oxide composite material. The present application also provides a composite wound dressing.
Description
Technical Field
The application relates to the technical field of antibacterial materials, in particular to a composite wound dressing and a preparation method thereof.
Background
The wound dressing is a medical material which is in direct contact with the surface of a wound and has wide clinical application. Has the function of preventing wound surface and systemic infection in the clinical treatment process. The antibacterial materials adopted by the existing traditional wound dressing are mainly divided into organic antibacterial agents, inorganic antibacterial agents and natural antibacterial agents.
The organic antibacterial agent mainly comprises guanidine salts and quaternary ammonium salts, is commonly used in polyethylene food packaging films to play an antibacterial role, but has poor thermal stability and generates certain cytotoxicity to human beings. The natural antibacterial agent is mainly extracted from natural plants, such as chitin, mustard, castor oil, horseradish, and the like, is simple and convenient to use, but has limited antibacterial action, poor heat resistance, low sterilization rate, no broad-spectrum long-acting use and small quantity. The inorganic antibacterial agent utilizes the antibacterial capacity of metals such as silver, copper, zinc and the like, and the metals (or ions thereof) such as silver, copper, zinc and the like are fixed on the surface of porous materials such as fluorite, silica gel and the like by methods such as physical adsorption ion exchange and the like to prepare the antibacterial agent, and then the antibacterial agent is added into a corresponding product to obtain the material with the antibacterial capacity, wherein the metals such as mercury, cadmium, lead and the like also have the antibacterial capacity but are harmful to human bodies; and ions such as copper, nickel, lead and the like have colors, which affect the appearance of the product, and zinc has certain antibacterial property, but the antibacterial strength of zinc is only 1/1000 of silver ions. Silver ion antibacterial agents have become common antibacterial agents because of their high antibacterial strength. However, in actual production, since silver is a noble metal, the production cost for preparing the antibacterial agent containing silver ions is high.
Disclosure of Invention
In view of the above, the present application provides a method for preparing a composite wound dressing to solve the above problems.
In addition, the composite wound dressing prepared by the preparation method of the composite wound dressing is also necessary to be provided.
In order to achieve the above object, the present application provides a method for preparing a composite wound dressing, comprising the following steps:
dispersing graphene oxide and a surfactant in water to obtain a graphene oxide dispersion liquid, wherein the mass ratio of the graphene oxide to the surfactant is (125) -300: 1;
adding a silver nitrate solution into the graphene oxide dispersion liquid to obtain a mixed solution, wherein the volume ratio of the graphene oxide dispersion liquid to the silver nitrate solution is 1: 1;
performing microwave treatment on the mixed solution, performing ultrasonic treatment, and finally performing centrifugal cleaning to obtain a nano silver/graphene oxide composite material;
adding chitosan into a solvent, dropwise adding acetic acid until the chitosan is completely dissolved, then adding the nano-silver/graphene oxide composite material, and performing ultrasonic dispersion to obtain a reaction solution, wherein the mass ratio of the chitosan to the nano-silver/graphene oxide composite material is (5-20): 6;
adding a cross-linking agent into the reaction solution, performing cross-linking on the nano-silver/graphene oxide composite material and the chitosan, removing the solvent, washing, and drying to obtain a chitosan/nano-silver/graphene oxide composite material;
mixing the chitosan/nano-silver/graphene oxide composite material with polypropylene, and processing to obtain chitosan/nano-silver/graphene oxide master batches;
dissolving a reinforcer in a hydrochloric acid solution, and adding the chitosan/nano silver/graphene oxide master batch and an additive to obtain a prefabricated product, wherein the additive is one of alginate or fibroin; and
and spraying the prefabricated product to a fiber net through high pressure to obtain the composite wound dressing with the bacteriostasis rate of more than 99.99%.
The application also provides a composite wound dressing prepared by the preparation method of the composite wound dressing.
According to the preparation method of the composite wound dressing, the graphene is used as the carrier, the high-efficiency antibacterial property of silver, the biocompatibility of the graphene and the antibacterial property of chitosan are utilized, the antibacterial rate of the composite wound dressing prepared by the preparation method is greater than 99.99%, the using amount of silver can be reduced, and the production cost is saved.
Detailed Description
The following describes embodiments of the present invention in detail. The following examples, given by way of illustration, are intended to illustrate the invention and are not to be construed as limiting the invention.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The chitosan is a product of natural polysaccharide chitin with partial acetyl removed, has various physiological functions of biodegradability, biocompatibility, nontoxicity, bacteriostasis, cancer resistance, lipid reduction, immunity enhancement and the like, and is widely applied to a plurality of fields of antibacterial agents, medical fibers, medical dressings, biomedical fields, medical absorbable materials and the like. The basic unit of the chitosan is glucosamine which is a substance existing in a human body, so the chitosan has good affinity with human body cells, has no rejection reaction, and can form cation clusters and induce the aggregation of red blood cells and platelets by carrying positive charges to promote blood coagulation, thereby achieving the effect of hemostasis. In addition, the chitosan can promote the growth of vascular endothelium, and has antibacterial property.
The main component of alginate is calcium alginate, which is a water insoluble substance. When the alginate meets liquid (such as seepage, blood and the like) rich in sodium ions, calcium ions and sodium ions are exchanged, calcium ions are released, and the sodium ions are combined with the alginic acid to form a hydrophilic gelatinous substance, so that the wound can be helped to maintain a wet environment, enhance autolytic debridement and promote the growth of granulation tissues, and meanwhile, the alginate has strong liquid absorption capacity and can absorb liquid which is 20 times of the weight of the alginate. Wherein, the autolysis debridement is to use a wet dressing to hydrate the wound, soften necrotic crust, dissolve necrotic tissue by the lysin produced by phagocytes and neutrophils in the exudate and absorb the exudate.
The application provides a preparation method of a composite wound dressing, which comprises the following steps:
step one, weighing 0.5-1.0 part by mass of graphite powder and 0.5-1.0 part by mass of sodium nitrate, adding the graphite powder and the sodium nitrate into a reaction bottle containing 4.6-5.6 parts by mass of concentrated sulfuric acid under ice bath, and adding 1.0-1.5 parts by mass of potassium permanganate (or phosphoric acid or sodium nitrate) while stirring to prepare a mixed solution;
keeping the temperature of the mixed solution at less than 15 ℃ for 1-3 h, taking out, stirring at room temperature for 3-4 days, adding deionized water for dilution, adding 1.0-2.0 parts by mass of 20-50% hydrogen peroxide, continuously stirring for 2-3h, and performing centrifugal separation to obtain a bright yellow precipitate;
washing the bright yellow precipitate for multiple times by using 0.05-1 mol/L dilute hydrochloric acid and distilled water until the pH value is 7, adding the distilled water into the bright yellow precipitate, performing ultrasonic treatment for 2-3h, centrifuging again, removing insoluble precipitate at the lower layer to obtain a suspension, filtering the suspension to obtain a solid product, and performing vacuum freeze drying on the solid product to obtain the graphene oxide. In some embodiments, the graphene oxide is a single layer or multiple layers.
And step two, mixing the graphene oxide prepared in the step one with a surfactant, dispersing the mixture in water, and performing ultrasonic treatment to obtain a graphene oxide dispersion liquid. The mass ratio of the graphene oxide to the surfactant is (125) -300) 1. In some embodiments, the surfactant is one of N, N-dimethylformamide, polyvinylpyrrolidone, or sodium dodecyl sulfate.
And adding a silver nitrate solution into the graphene oxide dispersion liquid, and carrying out ultrasonic treatment for 10min to obtain a mixed solution. Wherein the volume ratio of the graphene oxide dispersion liquid to the silver nitrate solution is 1: 1. And carrying out microwave treatment on the mixed solution. In some embodiments, the microwave treatment power is 100W-200W and the treatment time is 1min-5 min. The N, N-dimethylformamide is decomposed under the condition of microwave high temperature to generate reducing gas (such as carbon monoxide), and anions in the silver nitrate solution can be reduced to silver simple substance, so that other reducing reagents are reduced from being introduced into the mixed solution, and the operation is simple. And (3) carrying out ultrasonic treatment for 2-3h after microwave treatment, and carrying out centrifugal cleaning to obtain the nano silver/graphene oxide composite material.
And step three, adding 5-10 parts of chitosan into a solvent, dropwise adding 5-10 parts of acetic acid (glacial acetic acid) until the chitosan is completely dissolved, then adding the nano-silver/graphene oxide composite material, and performing ultrasonic dispersion to obtain a reaction solution. Wherein the mass ratio of the chitosan to the nano silver/graphene oxide composite material is (5-20): 6. when the mass ratio of the chitosan to the nano-silver/graphene oxide composite material is less than 5:6, the chitosan is less in content in the prepared chitosan/nano-silver/graphene oxide composite material, the hemostatic effect of the chitosan is not obvious, and the bacteriostatic effect of the chitosan is not obvious. When the mass ratio of the chitosan to the nano-silver/graphene oxide composite material is greater than 20:6, the antibacterial effect of the obtained chitosan/nano-silver/graphene oxide composite material is reduced due to the excessive content of the chitosan.
And adding a cross-linking agent into the reaction solution, carrying out cross-linking condensation reaction on the nano-silver/graphene oxide composite material and the chitosan to obtain a solution, removing the solvent in the solution, washing, and drying to obtain the chitosan/nano-silver/graphene oxide composite material.
In some embodiments, the crosslinking agent is glutaraldehyde. The mass ratio of the cross-linking agent in the solution is 2-7%. When the mass ratio of the cross-linking agent in the solution is less than 2%, the content of the cross-linking agent is low, which may result in incomplete cross-linking of the nano silver/graphene oxide composite material and the chitosan. When the mass ratio of the cross-linking agent in the solution is more than 7%, the content of the cross-linking agent is too large, and the excessive cross-linking agent can be removed by washing for many times, so that the preparation process is increased.
In some embodiments, the solvent is one of acetone or disodium edetate.
And step four, mixing the chitosan/nano-silver/graphene oxide composite material with polypropylene, adding the mixture into a double-screw extruder, mixing and extruding the mixture, and granulating the mixture to obtain the chitosan/nano-silver/graphene oxide master batch. In some embodiments, the chitosan/nano-silver/graphene oxide composite material accounts for 5% or more of the mass ratio of the chitosan/nano-silver/graphene oxide master batch. When the ratio is less than 5%, the chitosan/nano silver/graphene oxide composite material in the prepared composite wound dressing is low, and the bacteriostasis rate of the composite wound dressing is less than 99.99%.
Dissolving a reinforcer in a hydrochloric acid solution, and adding the chitosan/nano-silver/graphene oxide master batch and an additive to obtain a prefabricated product, wherein the additive is one of alginate or fibroin. In some embodiments, the enhancer is one of glutaraldehyde, glyoxal, or 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride/N-hydroxysuccinimide [ EDC/NHS for short ].
And spraying the prefabricated product to a fiber net through high pressure to obtain the composite wound dressing with the bacteriostasis rate of more than 99.99%. In some embodiments, the fiber mesh is one of alginate or fibroin.
According to the preparation method of the composite wound dressing, the graphene is used as the carrier, the high-efficiency antibacterial property of silver, the biocompatibility of the graphene and the antibacterial property of chitosan are utilized, the antibacterial rate of the prepared composite wound dressing is greater than 99.99%, and the chitosan is used for replacing part of silver in the composite wound dressing, so that the usage amount of silver in the wound dressing can be reduced, and the production cost is saved.
The application also provides a composite wound dressing prepared by the preparation method of the composite wound dressing.
The scheme of the invention will be explained with reference to the examples. It will be appreciated by persons skilled in the art that the following examples are illustrative only and are not to be construed as limiting the invention. Reagents, software and equipment not specifically submitted to the following examples are conventional commercial products or open sources unless otherwise submitted.
Example 1
(1) Preparation of graphene oxide
Respectively weighing 1.0 part by mass of graphite powder and sodium nitrate, adding the graphite powder and the sodium nitrate into a reaction bottle containing 5.6 parts by mass of concentrated sulfuric acid in an ice bath, adding 1.5 parts by mass of potassium permanganate while stirring, and carrying out constant-temperature reaction at about 10 ℃ for 3 hours to obtain a mixed solution. And taking out the mixed solution, stirring the mixed solution for 3 days at 37 ℃, then diluting the mixed solution by using deionized water, adding 2.0 parts of 25% hydrogen peroxide, continuously stirring the mixed solution for 2 hours, and performing centrifugal separation to obtain a bright yellow precipitate.
The bright yellow precipitate was washed several times with 0.1moL/L dilute hydrochloric acid and distilled water successively to a pH of approximately 7. Adding the distilled water into the bright yellow precipitate, performing ultrasonic treatment for 3 hours, centrifuging again, removing insoluble precipitate at the lower layer to obtain a suspension, filtering the suspension to obtain a solid product, and performing vacuum freeze drying on the solid product to obtain the graphene oxide.
(2) Preparation of nano-silver/graphene oxide composite material
1.25 parts by mass of the graphene oxide prepared above and 0.006 part of N, N-Dimethylformamide (DMF) were dispersed in 20mL of an aqueous solution, wherein the DMF served as both a solvent and a reducing agent, and the dispersion was homogenized by sonication for 1 hour to obtain a graphene oxide dispersion.
Adding AgNO into graphene oxide dispersion liquid3Solution of graphene oxide dispersion with AgNO3The volume ratio of the solution was 1:1, and after 10 minutes of ultrasonic treatment, a mixed solution was obtained. And (3) irradiating the mixed solution for 1min by using microwaves (high fire 100W), continuing performing ultrasonic treatment for 3h, and then performing centrifugal cleaning to obtain the nano silver/graphene oxide composite material.
(3) Preparation of chitosan/nano silver/graphene oxide composite material
Adding 10 parts of chitosan into 5 parts by mass of disodium ethylene diamine tetraacetate solution, dropwise adding 6 parts of acetic acid to dissolve the chitosan, adding the prepared 6 parts of nano silver/graphene oxide composite material, and performing ultrasonic dispersion uniformly to obtain a reaction solution. Adding glutaraldehyde into the reaction liquid, wherein the mass of the glutaraldehyde accounts for 3% of that of the reaction liquid, so that the nano-silver/graphene oxide and chitosan are subjected to condensation reaction, and then removing the solvent, washing and drying to obtain the chitosan/nano-silver/graphene oxide material.
(4) Preparation of chitosan/nano-silver/graphene oxide composite wound dressing
Mixing the prepared chitosan/nano-silver/graphene oxide material with polypropylene, and processing to obtain the chitosan/nano-silver/graphene oxide master batch. Wherein the chitosan/nano-silver/graphene oxide material accounts for 5% of the mass of the chitosan/nano-silver/graphene oxide master batch.
Dissolving 2 parts by mass of enhancer EDC/NHS in 0.2% hydrochloric acid solution, and adding 90 parts of chitosan/nano-silver/graphene oxide master batch and 8 parts of alginate for dissolution. And then spraying high-pressure micro water flow onto one layer of fiber mesh or a plurality of layers of fiber meshes to enable the fiber meshes to be attached with chitosan/nano silver/graphene oxide materials, thus obtaining the chitosan/nano silver/graphene oxide composite wound dressing used for the wound.
To further verify the effectiveness of the composite wound dressing prepared in the above examples, the following tests were also performed.
1. Instruments and materials used for testing:
nutrient agar, a culture dish, a vertical pressure steam sterilizer, an electric heating blast drying box, a biochemical incubator, an electric heating constant temperature incubator, a graduated suction pipe and the like; staphylococcus aureus (ATCC6538), escherichia coli (ATCC25922), candida albicans (ATCC10231), all passage 4; 4 batches of chitosan/nano silver/graphene oxide dressing have the following batch numbers: a. b, c and d.
2. The test method comprises the following steps:
flask oscillation method for detecting antibacterial performance of chitosan/nano-silver/graphene oxide composite wound dressing
The antibacterial performance (such as staphylococcus aureus, escherichia coli and candida albicans) of 4 batches of chitosan/nano silver/graphene oxide composite wound dressings was tested by adopting a flask oscillation method with optimized conditions.
The specific method comprises the following steps: the chitosan/nano-silver/graphene oxide composite wound dressing is cut into a size of 1cm multiplied by 1cm, accurately weighed (0.75g), and then placed in a sterile conical flask to serve as a sample piece group. The web material was used as a control panel set, while an unspiked panel set was prepared and set as f. 70mL of phosphate buffer solution (0.03moL/L, PBS) and 5mL of staphylococcus aureus bacteria solution/escherichia coli bacteria solution/candida albicans bacteria solution are respectively added into the three groups of sample slice groups, and shaking culture is carried out for 1h at 37 ℃ and 200 rpm/min. Samples were taken at 0h and 1h, respectively, and the change in bacterial count was calculated. Each batch of product test was repeated 3 times and the average inhibition rate was calculated.
Calculating the bacteriostatic rate: according to the formula, X is (A-B)/A X100 percent, and X is the bacteriostasis rate; a is the average colony number of the sample before oscillation; b is the average colony number of the sample after oscillation. And (4) judging the standard: the difference value of the number of bacterial colonies before and after the oscillation of the sample-free group is within 10 percent, the difference value between the bacteriostatic rate of the test sample and the bacteriostatic rate of the control sample is more than 26 percent, and the product can be judged to have the antibacterial effect.
TABLE 1 Difference (%)% before and after the shaking culture of the three bacteria
As can be seen from Table 1, the differences of the numbers of the colonies of Staphylococcus aureus, Escherichia coli and Candida albicans before and after 1h of oscillation at 37 ℃ and 200rpm/min are within 10%, which indicates that the test is effective.
TABLE 2 test 4 dressing groups (a, b, c, d) and web (f) for S.aureus inhibition (%)
According to the data in table 2, 4 batches of chitosan/nano silver/graphene oxide composite wound dressings have an effect on staphylococcus aureus for 1 hour, the bacteriostasis rates are all greater than or equal to 99.99% and far exceed the judgment standard (the product can be judged to have an antibacterial effect if the difference between the bacteriostasis rate of a test sample and the bacteriostasis rate of a control sample is greater than 26% according to the standard specification), and this shows that 4 batches of chitosan/nano silver/graphene oxide composite wound dressings have an excellent bacteriostasis effect on staphylococcus aureus.
Table 3 test 4 groups of dressings (a, b, c, d) and fiber net (f) for their respective inhibition rates for Escherichia coli (%)
According to the data in table 3, 4 batches of chitosan/nano silver/graphene oxide composite wound dressing have an effect on coliform bacteria for 1 hour, the inhibition rates are all greater than or equal to 99.99%, and far exceed the judgment standard (the difference between the inhibition rate of a test sample and the inhibition rate of a control sample is greater than 26%, the product can be judged to have an antibacterial effect), which indicates that 4 batches of chitosan/nano silver/graphene oxide composite wound dressing have an excellent antibacterial effect on the coliform bacteria.
TABLE 4 test of inhibition (%), respectively, of Candida albicans by 4 groups of dressings (a, b, c, d) and fibrous web (f)
According to the data in table 4, 4 batches of chitosan/nano silver/graphene oxide composite wound dressing have an effect on candida albicans for 1 hour, the bacteriostasis rates are all greater than or equal to 99.99% and far exceed the judgment standard (the product can be judged to have an antibacterial effect if the difference between the bacteriostasis rate of the test sample and the bacteriostasis rate of the control sample is greater than 26% specified by the standard), which indicates that 4 batches of chitosan/nano silver/graphene oxide composite wound dressing have an excellent bacteriostasis effect on candida albicans.
Although the present invention has been described in detail with reference to the above embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the spirit and scope of the invention.
Claims (9)
1. A preparation method of the composite wound dressing is characterized by comprising the following steps:
dispersing graphene oxide and a surfactant in water to obtain a graphene oxide dispersion liquid, wherein the mass ratio of the graphene oxide to the surfactant is (125) -300: 1;
adding a silver nitrate solution into the graphene oxide dispersion liquid to obtain a mixed solution, wherein the volume ratio of the graphene oxide dispersion liquid to the silver nitrate solution is 1: 1;
performing microwave treatment on the mixed solution, performing ultrasonic treatment, and finally performing centrifugal cleaning to obtain a nano silver/graphene oxide composite material;
adding chitosan into a solvent, dropwise adding acetic acid until the chitosan is completely dissolved, then adding the nano-silver/graphene oxide composite material, and performing ultrasonic dispersion to obtain a reaction solution, wherein the mass ratio of the chitosan to the nano-silver/graphene oxide composite material is (5-20): 6;
adding a cross-linking agent into the reaction solution, performing cross-linking on the nano-silver/graphene oxide composite material and the chitosan, removing the solvent, washing, and drying to obtain a chitosan/nano-silver/graphene oxide composite material;
mixing the chitosan/nano-silver/graphene oxide composite material with polypropylene, and processing to obtain chitosan/nano-silver/graphene oxide master batches;
dissolving a reinforcer in a hydrochloric acid solution, and adding the chitosan/nano silver/graphene oxide master batch and an additive to obtain a prefabricated product, wherein the additive is one of alginate or fibroin; and
and spraying the prefabricated product to a fiber net through high pressure to obtain the composite wound dressing with the bacteriostasis rate of more than 99.99%.
2. The method for preparing a composite wound dressing according to claim 1, wherein the chitosan/nano silver/graphene oxide composite material accounts for 5% or more of the chitosan/nano silver/graphene oxide master batch by mass.
3. A method of preparing a composite wound dressing as claimed in claim 1, wherein the power of the microwave treatment is 100W-200W for 1min-5 min.
4. A method of preparing a composite wound dressing as claimed in claim 1, in which the fortifier is one of glutaraldehyde, glyoxal or 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride/N-hydroxysuccinimide.
5. A method of preparing a composite wound dressing as claimed in claim 1, in which the surfactant is one of N, N-dimethylformamide, polyvinylpyrrolidone or sodium dodecylsulphonate.
6. A method of preparing a composite wound dressing as claimed in claim 1, in which the solvent is one of acetone or disodium edetate.
7. A method of preparing a composite wound dressing according to claim 1, wherein the cross-linking agent is glutaraldehyde.
8. A method of preparing a composite wound dressing according to claim 1, wherein the preparation of graphene oxide comprises the steps of:
adding 0.5-1.0 part by mass of graphite powder and 0.5-1.0 part by mass of sodium nitrate into a reaction bottle containing 4.6-5.6 parts by mass of concentrated sulfuric acid under ice bath, and adding 1.0-1.5 parts by mass of one of potassium permanganate, phosphoric acid or sodium nitrate while stirring to prepare a mixed solution;
keeping the temperature of the mixed solution at less than 15 ℃ for reaction for 1-3 h, taking out the mixed solution, stirring the mixed solution at room temperature for 3-4 days, adding deionized water for dilution, adding 1.0-2.0 parts of 20-50% hydrogen peroxide, continuously stirring the mixed solution for 2-3h, and performing centrifugal separation to obtain a bright yellow precipitate;
washing the bright yellow precipitate for multiple times by using 0.05-1 mol/L diluted hydrochloric acid and distilled water until the pH value is 7, adding the distilled water into the bright yellow precipitate, performing ultrasonic treatment for 2-3h, centrifuging again, removing insoluble precipitate at the lower layer to obtain a suspension, filtering the suspension to obtain a solid product, and performing vacuum freeze drying on the product to obtain the graphene oxide.
9. A composite wound dressing prepared by the method of making a composite wound dressing according to any one of claims 1 to 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110938732.5A CN113577363A (en) | 2021-08-16 | 2021-08-16 | Composite wound dressing and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110938732.5A CN113577363A (en) | 2021-08-16 | 2021-08-16 | Composite wound dressing and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113577363A true CN113577363A (en) | 2021-11-02 |
Family
ID=78258146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110938732.5A Pending CN113577363A (en) | 2021-08-16 | 2021-08-16 | Composite wound dressing and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113577363A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113278243A (en) * | 2021-06-10 | 2021-08-20 | 贡吉 | Antibacterial and antistatic ABS plastic for household appliance shell and preparation method thereof |
| CN116920152A (en) * | 2023-07-28 | 2023-10-24 | 中国人民解放军东部战区总医院 | Preparation method and application of graphene oxide trauma dressing capable of stopping bleeding rapidly |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1851087A (en) * | 2006-06-08 | 2006-10-25 | 升联国际生物科技股份有限公司 | Nano silver fiber net, and its electrostatic spinning method and use |
| CN103191464A (en) * | 2013-04-07 | 2013-07-10 | 西南交通大学 | Method for preparing antibacterial porous oxidized graphene/chitosan composite bracket |
| KR20160139264A (en) * | 2015-05-27 | 2016-12-07 | 국방과학연구소 | 3-dimenstinal nanofiber membrane and Method of manufacturing the same using liquid collector |
| CN109045339A (en) * | 2018-08-29 | 2018-12-21 | 郑州工程技术学院 | A kind of medical compound antiseptic dressing and preparation method thereof |
| CN109675084A (en) * | 2018-12-17 | 2019-04-26 | 深圳先进技术研究院 | Antiseptic dressing and its preparation method and application |
| CN110772659A (en) * | 2019-06-28 | 2020-02-11 | 复向医药科技(上海)有限公司 | Preparation method of chitosan graphene nano medical dressing for resisting bacteria and promoting wound healing |
| CN111972435A (en) * | 2019-05-24 | 2020-11-24 | 浙江海纳新材料科技有限公司 | Preparation method of nano-silver-graphene oxide composite material |
-
2021
- 2021-08-16 CN CN202110938732.5A patent/CN113577363A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1851087A (en) * | 2006-06-08 | 2006-10-25 | 升联国际生物科技股份有限公司 | Nano silver fiber net, and its electrostatic spinning method and use |
| CN103191464A (en) * | 2013-04-07 | 2013-07-10 | 西南交通大学 | Method for preparing antibacterial porous oxidized graphene/chitosan composite bracket |
| KR20160139264A (en) * | 2015-05-27 | 2016-12-07 | 국방과학연구소 | 3-dimenstinal nanofiber membrane and Method of manufacturing the same using liquid collector |
| CN109045339A (en) * | 2018-08-29 | 2018-12-21 | 郑州工程技术学院 | A kind of medical compound antiseptic dressing and preparation method thereof |
| CN109675084A (en) * | 2018-12-17 | 2019-04-26 | 深圳先进技术研究院 | Antiseptic dressing and its preparation method and application |
| CN111972435A (en) * | 2019-05-24 | 2020-11-24 | 浙江海纳新材料科技有限公司 | Preparation method of nano-silver-graphene oxide composite material |
| CN110772659A (en) * | 2019-06-28 | 2020-02-11 | 复向医药科技(上海)有限公司 | Preparation method of chitosan graphene nano medical dressing for resisting bacteria and promoting wound healing |
Non-Patent Citations (1)
| Title |
|---|
| 李娅娅: "《微波辅助制备石墨烯/银复合材料及其抗菌性能研究》", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113278243A (en) * | 2021-06-10 | 2021-08-20 | 贡吉 | Antibacterial and antistatic ABS plastic for household appliance shell and preparation method thereof |
| CN113278243B (en) * | 2021-06-10 | 2022-09-02 | 广州盈邦智能技术有限公司 | Antibacterial and antistatic ABS plastic for household appliance shell and preparation method thereof |
| CN116920152A (en) * | 2023-07-28 | 2023-10-24 | 中国人民解放军东部战区总医院 | Preparation method and application of graphene oxide trauma dressing capable of stopping bleeding rapidly |
| CN116920152B (en) * | 2023-07-28 | 2024-01-23 | 中国人民解放军东部战区总医院 | Preparation method and application of graphene oxide trauma dressing capable of stopping bleeding rapidly |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6290426B2 (en) | Method for producing swellable polymer fiber and swellable polymer fiber produced by the method | |
| CN106048892B (en) | A kind of preparation method for the GO/SA/PVA composite nano-fiber membranes being loaded with nano silver particles | |
| Sacco et al. | Silver-containing antimicrobial membrane based on chitosan-TPP hydrogel for the treatment of wounds | |
| CN113577363A (en) | Composite wound dressing and preparation method thereof | |
| Elbarbary et al. | Radiation synthesis and characterization of polyvinyl alcohol/chitosan/silver nanocomposite membranes: antimicrobial and blood compatibility studies | |
| Cao et al. | Multifunctional dopamine modification of green antibacterial hemostatic sponge | |
| WO2015165400A1 (en) | Hygroscopic silver-containing product containing silver thiosulfate complex or silver-ammonia complex, and preparation method thereof | |
| CN113637183A (en) | Modified graphene-loaded nano-silver/polyvinyl alcohol antibacterial hydrogel and preparation method thereof | |
| Öztürk et al. | Preparation and characterization of ciprofloxacin‐loaded alginate/chitosan sponge as a wound dressing material | |
| CN112451738B (en) | Silver ion polysaccharide polymer antibacterial dressing and preparation method and application thereof | |
| CN102373618B (en) | Silver-carried alginic acid fiber and preparation method thereof | |
| CN104928799A (en) | Preparation method for sustainable antibacterial nano-zinc oxide alginate fibers | |
| EP1601309B1 (en) | Wound management fibres | |
| CN102321935A (en) | Soluble alginate/carboxymethyl carrageenan composite antibacterial fiber and preparation method thereof | |
| CN114404646B (en) | CM-beta-CD supported tannic acid polyacrylamide type double-network antibacterial hydrogel | |
| Zheng et al. | Preparation and hemostatic mechanism of bioactive glass-based membrane-like structure camouflage composite particles | |
| CN114045577A (en) | Silver-containing hydrogel type alginate fiber and preparation method thereof | |
| CN106924806A (en) | A kind of cupric carboxymethyl chitosan sodium alginate support, its preparation method and application | |
| WO2018223743A1 (en) | Silver-containing antibacterial product, and preparation method thereof | |
| CN111658815B (en) | Antibacterial alginate dressing and preparation method thereof | |
| CN107325319A (en) | A kind of preparation method and application of porous Kynoar composite Nano Ag films | |
| CN115850733A (en) | Injectable nano clay hydrogel and preparation method and application thereof | |
| JPH04231062A (en) | Antimicrobial medical product | |
| Liu et al. | Antibacterial activity of pH‐sensitive genipin cross‐linked chitosan/poly (ethylene glycol)/silver nanocomposites | |
| CN116535540B (en) | Quaternized modified chitin, sponge thereof, preparation method of porous microsphere and application of quaternized modified chitin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211102 |
|
| RJ01 | Rejection of invention patent application after publication |